Abstracts Archive - Page 2245 of 2607 - ACR Meeting Abstracts

Abstract Number: 2820 • 2013 ACR/ARHP Annual Meeting
Disease-Regulated Local Interleukin-10 Gene Therapy Diminishes Synovitis and Articular Cartilage Damage In Experimental Arthritis
Eline A. Vermeij¹, Mathijs G.A. Broeren¹, Miranda B. Bennink¹, Onno J. Arntz², Inger Gjertsson³, Wim B. van den Berg¹ and Fons A.J. van de Loo¹, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a chronic destructive autoimmune disease and in most patients the disease follows an intermittent course with periods of exacerbation and…
Abstract Number: 2821 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Selective Manipulation Of The CD28 Co-Stimulation Pathway In The Rhesus Monkey Model Of Collagen-Induced Arthritis
Michel P.M. Vierboom¹, Elia Breedveld¹, Bert 't Hart¹, Flora Coulon² and Bernard Vanhove³, ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²UMR-S 1064, Institut National de la Santé et de la Recherche Médicale, Nantes, France, ³Institut de Transplantation - Urologie - Néphrologie, INSERM UMR-S 1064, Nantes, France
Background/Purpose: T-cells are important in the pathogenesis of rheumatoid arthritis (RA). T-cell activation depends on at least two signals. Next to the first signal that…
Abstract Number: 2822 • 2013 ACR/ARHP Annual Meeting
IKKε Deficiency Prolongs Neutrophil Survival Paradoxically Prolonging Inflammation In The Absence Of a Type I Interferon Response
Maripat Corr¹, Christopher Chung², Seong-Kyu Kim³, D. L Boyle⁴ and G. S. Firestein⁵, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Deficiency of the IKK-related kinases IKKε synergizes with the anti-inflammatory effects of IFNß in a murine model of arthritis., and this effect is mediated…
Abstract Number: 2823 • 2013 ACR/ARHP Annual Meeting
FLIP Deficiency In Dendritic Cells Promotes Spontaneous Inflammatory and Erosive Arthritis
Qi Quan Huang¹, Harris R. Perlman², Robert Birkett³, Renee E. Koessler¹, Syamal K. Datta⁴ and Richard M. Pope⁵, ¹Medicine/Rheumatology, Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ⁴Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose: FLIP is an anti-apoptotic protein induced by chronic inflammation. In this study a mouse line with FLIP deleted in CD11c+ dendritic cells (DCs), that…
Abstract Number: 2824 • 2013 ACR/ARHP Annual Meeting
Urinary Microalbumin Is Associated With Arterial Stiffness In Patients With Rheumatoid Arthritis
Karima Becetti¹, Annette M. Oeser², Joseph F. Solus³, Paolo Raggi⁴, C. Michael Stein⁵ and Cecilia P. Chung¹, ¹Medicine, Vanderbilt University, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt Medical Center, Nashville, TN, ⁴University of Alberta, Edmonton, AB, Canada, ⁵School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk for cardiovascular disease (CVD). Urinary microalbumin is a risk factor for CVD in the general…
Abstract Number: 2825 • 2013 ACR/ARHP Annual Meeting
The Influence Of Early Menopause On Cardiovascular Risk In Women With Rheumatoid Arthritis
Emily Pfeifer¹, Cynthia S. Crowson², Shreyasee Amin³, Sherine E. Gabriel⁴ and Eric L. Matteson⁵, ¹Department of Medicine, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lifetime exposure to female sex hormones may play a role in the development and severity of rheumatoid arthritis (RA). These same hormones have also…
Abstract Number: 2826 • 2013 ACR/ARHP Annual Meeting
Performance Of Five Current Risk Algorithms In Predicting Cardiovascular Events In Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Calin Popa¹, Alfons A. den Broeder², Anne G. Semb³, Tracey Toms⁴, George Kitas⁴, Piet L.C.M. van Riel¹ and Jaap Fransen⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Cardiovascular risk in rheumatoid arthritis (RA) is increased. The cardiovascular (CV) risk algorithms used in the general population may underestimate the risk of cardiovascular…
Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed⁴, Jeffrey D. Greenberg⁵, Ashwini Shewade², Daniel H. Solomon⁶, Joel M. Kremer⁷ and Tanya Sommers⁴, ¹Columbia University, New York, NY, ²Genentech Inc., South San Francisco, CA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴CORRONA, Inc., Southborough, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
Abstract Number: 2828 • 2013 ACR/ARHP Annual Meeting
The Performance Of The Original and An Updated Cardiovascular Risk Algorithm (SCORE) In Patients With Rheumatoid Arthritis
Elke.E.A. Arts¹, Calin Popa¹, Alfons A. den Broeder², Anne Grete Semb³, Tracey Toms⁴, George Kitas⁴, Piet L.C.M. van Riel¹ and Jaap Fransen¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom
Background/Purpose: Cardiovascular (CV) risk in rheumatoid arthritis (RA) is increased. The CV risk algorithms for the general population may underestimate the risk of cardiovascular disease…
Abstract Number: 2829 • 2013 ACR/ARHP Annual Meeting
Statin Adherence and Risk Of Mortality In Patients With Rheumatoid Arthritis: A Population-Based Study
Mary De Vera^1,2, Michal Abrahamowicz³ and Diane Lacaille⁴, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: Poor adherence with statin therapy is associated with increased mortality in the general population, but no corresponding data are available among patients with rheumatoid…
Abstract Number: 2830 • 2013 ACR/ARHP Annual Meeting
First Stage Of a Simon’s Two-Stage Optimal Approach Supports Placental Transfer Of Hydroxychloroquine and a Reduced Recurrence Rate Of The Cardiac Manifestations Of Neonatal Lupus
Peter M. Izmirly¹, Nathalie Costedoat-Chalumeau², Amit Saxena³, Amanda Zink⁴, Zoey Smith³, Deborah Friedman⁵ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Internal Medicine, Hopital Cochin, Paris, France, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴NYU Hospital for Joint Diseases, New York University School of Medicine, New York, NY, ⁵Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: A previous case control study suggested that hydroxychloroquine (HCQ) might prevent the development of cardiac Neonatal Lupus (cardiac NL) in anti-SSA/Ro antibody (ab) exposed…
Abstract Number: 2831 • 2013 ACR/ARHP Annual Meeting
Increased Risk Of Autism Spectrum Disorders In Children Born To Women With SLE: Preliminary Data From The O S L E R Cohort
Evelyne Vinet¹, Susan Scott², Christian A. Pineau³, Lawrence Joseph⁴, Ann E. Clarke⁵, Eric Fombonne⁶, Robert W. Platt⁴ and Sasha Bernatsky⁷, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Recent experimental data suggest in utero exposure to maternal antibodies and cytokines as important risk factors for autism spectrum disorders (ASD). Interestingly, women with…
Abstract Number: 2832 • 2013 ACR/ARHP Annual Meeting
The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus
Julie Barsalou¹, Edgar Jaeggi² and Earl D. Silverman¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Neonatal Lupus (NLE) results from passive transfer of anti-Ro and/or anti-La antibodies to the fetus during gestation. It has been suggested that prenatal exposure…
Abstract Number: 2833 • 2013 ACR/ARHP Annual Meeting
Increased Cardiac Septal Defects In Children Born To Women With Systemic Lupus Erythematosus: Results From The O S L E R Study
Evelyne Vinet¹, Susan Scott², Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁴ and Sasha Bernatsky⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Cardiac septal defects, which include atrial septal defects (ASD) and ventricular septal defects (VSD), are the most frequent congenital heart anomalies in the general…
Abstract Number: 2834 • 2013 ACR/ARHP Annual Meeting
Maternal data Analysis Of The French Registry Of 205 Cases Of Immune Congenital Heart Block (neonatal lupus)
Kateri Levesque¹, Nathalie Morel², Gaëlle Guettrot-Imbert³, Mohamed Hamidou⁴, Jean Loup Pennaforte⁵, Pauline Orquevaux⁵, Jean-Charles Piette⁶, Christophe Deligny⁷, Zahir Amoura⁸, Olivier Meyer⁹, Olivier Fain¹⁰, Agathe Masseau¹¹, Holly Bezanahary¹², Pascal Cathebras¹³, Elizabeth Diot¹⁴, Yves Dulac¹⁵, Loic Guillevin¹⁶, Eric Hachulla¹⁷, Jean-Louis Pasquali¹⁸, Anne Besancon-Bergelin¹⁹, Bernard Bonnotte²⁰, Jérome Lebidois²¹, Alice Maltret²², Elisabeth Villain²² and Nathalie Costedoat-Chalumeau²³, ¹Medicine Interne, Hopital Cochin, Paris, France, ²Internal Medicine, COCHIN, Paris, France, ³Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁴CHU Hôtel Dieu, Nantes, Nantes, France, ⁵Hu Robert Debre, CHU Reims, Reims, France, ⁶Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ⁷Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ⁸Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁹Rheumatology, Bichat University Hospital, Paris, France, ¹⁰Internal Medicine, Jean Verdier Hospital, Bondy, France, ¹¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹²Internal Medicine, University Hospital of Limoges, Limoges, France, ¹³Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹⁴Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ¹⁵University Hospital Toulouse, Paris, France, ¹⁶Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁷Internal Medicine, University Hospital Lilles, Lille CEDEX, France, ¹⁸Strasbourg University, Hospital, CNRS UPR 3572, Strasbourg, France, ¹⁹Internal Medicine, Le Mans Hospital, Le Mans, France, ²⁰Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²¹Cardiac Institute, Paris, France, ²²Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ²³Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Congenital heart block (CHB) occurs in 1 to 2 % of pregnancies exposed to anti-SSA antibodies. Few data are available regarding the risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].